(Q33370672)

English

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

0 references

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

M E Trudeau

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Crump

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

D Charpentier

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Yelle

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Bordeleau

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Matthews

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E Eisenhauer

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

24 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

952-956

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Response of brain metastases from breast cancer to systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

MGMT: its role in cancer aetiology and cancer therapeutics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Oral alkylating agents for breast cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDL056

21 January 2018

Identifiers

10.1093/ANNONC/MDL056

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33370672&oldid=1976265450"